PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer

Abstract excerpt

Immunotherapy (IO) is an effective treatment for various cancers; however, the benefits are modest for small cell lung cancer (SCLC). The poor response of SCLC to anti-PD-1/PD-L1 IO is due in part to the lack of cytotoxic T cells because of limited chemokine expression from SCLC tumors. Immunogenic radiosensitizers that enhance chemokine expression may be a promising strategy forward. Here, we show that the PARP...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations
• Share to PARP inhibition in cancer therapy